INE068V01023
INE068V01023
GLAND PHARMA LIMITED
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2026 | 2025 | Change % |
|---|---|---|---|
| Total Revenue | 64.029.020.000 | 55.836.260.000 | 14.7% |
| Cost of Revenue | 22.429.300.000 | 20.903.810.000 | 7.3% |
| Gross Profit | 41.599.720.000 | 34.932.450.000 | 19.1% |
| 29.533.480.000 | 26.032.430.000 | 13.4% | |
| Operating Income | 12.066.240.000 | 8.900.020.000 | 35.6% |
| Pretax Income | 14.645.800.000 | 10.626.580.000 | 37.8% |
| Net Income Common Stockholders | 10.273.160.000 | 6.985.260.000 | 47.1% |
| -- | -- | -- | |
| -- | -- | -- |